✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Fyremadel is a drug marketed by Sun Pharm and is included in one NDA.
The generic ingredient in FYREMADEL is ganirelix acetate. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ganirelix acetate profile page.
A generic version of FYREMADEL was approved as ganirelix acetate by ORGANON USA INC on July 29th, 1999.
Pharmacology for FYREMADEL
|Drug Class|| Gonadotropin Releasing Hormone Receptor Antagonist |
|Mechanism of Action|| Gonadotropin Releasing Hormone Receptor Antagonists |
|Physiological Effect||Decreased GnRH Secretion |
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Sun Pharm||FYREMADEL||ganirelix acetate||INJECTABLE;INJECTION||204246-001||Nov 30, 2018||AP||RX||No||No||See Plans and Pricing||See Plans and Pricing||See Plans and Pricing|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|